On March 2nd, 2020, Simcere Pharmaceutical Group announced that the company has appointed Dr. Kevin Oliver as Senior Vice President in charge of Business Development in the United states. He will report directly to the Company Chairman and CEO.
The Chairman and CEO of Simcere comments: "Dr. Oliver has a broad strategic vision and rich experience in pharmaceutical R&D and BD management. I believe that his presence will play an active role in the implement of our BD strategy, exploration of innovation and human resources, as well as enrichment of product pipelines, and promote the company’s growth outwards. "
Dr. Kevin Oliver says: "I am delighted to be joining Simcere as SVP of Business Development. It is an honor to be part of such a dynamic and professional team and I very much look forward to what I believe we will achieve together. We are part of a competitive biopharmaceutical ecosystem that increasingly relies on successful alliances. It will therefore be a top priority for us to bring our collective experience together, along with that of our R&D, commercial and manufacturing colleagues, to establish Simcere as the innovative 'partner of choice'."
A brief biography of Dr. Kevin Oliver
Dr. Kevin Oliver obtained his bachelor's degree in Immunology from King's College London and a Ph.D. degree in Pathology from Cambridge University. Prior to Simcere, Dr. Oliver has held R&D and BD management positions in Merck for more than 20 years. In 2014, he became the Head of Alcon's BD-Global External Alliances group.
Dr. Kevin Oliver holds nearly 30 years’ experience in R&D, Corporate Strategy, BD and M&A. He is an outstanding expert and leader in opportunity sourcing, project evaluation, transaction negotiation and alliance management.